37 related articles for article (PubMed ID: 14985536)
1. Construction and characterization of a kappa opioid receptor devoid of all free cysteines.
Ott D; Frischknecht R; Plückthun A
Protein Eng Des Sel; 2004 Jan; 17(1):37-48. PubMed ID: 14985536
[TBL] [Abstract][Full Text] [Related]
2. Engineering and functional immobilization of opioid receptors.
Ott D; Neldner Y; Cèbe R; Dodevski I; Plückthun A
Protein Eng Des Sel; 2005 Mar; 18(3):153-60. PubMed ID: 15790572
[TBL] [Abstract][Full Text] [Related]
3. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
Wang HY; Friedman E; Olmstead MC; Burns LH
Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
[TBL] [Abstract][Full Text] [Related]
4. N-Glycosylation of the human kappa opioid receptor enhances its stability but slows its trafficking along the biosynthesis pathway.
Li JG; Chen C; Liu-Chen LY
Biochemistry; 2007 Sep; 46(38):10960-70. PubMed ID: 17711303
[TBL] [Abstract][Full Text] [Related]
5. Conformational change of the transmembrane helices II and IV of metabotropic glutamate receptor involved in G protein activation.
Yamashita T; Terakita A; Kai T; Shichida Y
J Neurochem; 2008 Jul; 106(2):850-9. PubMed ID: 18445134
[TBL] [Abstract][Full Text] [Related]
6. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
[TBL] [Abstract][Full Text] [Related]
7. Overexpression and functional characterisation of the human melanocortin 4 receptor in Sf9 cells.
Dolby V; Collén A; Lundqvist A; Cronet P
Protein Expr Purif; 2004 Oct; 37(2):455-61. PubMed ID: 15358370
[TBL] [Abstract][Full Text] [Related]
8. Cloning, heterologous expression and pharmacological characterization of a kappa opioid receptor from the brain of the rough-skinned newt, Taricha granulosa.
Bradford CS; Walthers EA; Searcy BT; Moore FL
J Mol Endocrinol; 2005 Jun; 34(3):809-23. PubMed ID: 15956349
[TBL] [Abstract][Full Text] [Related]
9. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
Xu H; Wang X; Wang J; Rothman RB
Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220
[TBL] [Abstract][Full Text] [Related]
10. Expression, purification, and initial structural characterization of rat orphan nuclear receptor NOR-1 LBD domain.
Razzera G; Vernal J; Portugal RV; Calgaro MR; Fernandez P; Zakin MM; Polikarpov I; Terenzi H
Protein Expr Purif; 2004 Oct; 37(2):443-9. PubMed ID: 15358368
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
[TBL] [Abstract][Full Text] [Related]
12. Mu-delta opioid receptor functional interaction: Insight using receptor-G protein fusions.
Snook LA; Milligan G; Kieffer BL; Massotte D
J Pharmacol Exp Ther; 2006 Aug; 318(2):683-90. PubMed ID: 16690720
[TBL] [Abstract][Full Text] [Related]
13. Expression pattern of fibroblast growth factors (FGFs), their receptors and antagonists in primary endothelial cells and vascular smooth muscle cells.
Antoine M; Wirz W; Tag CG; Mavituna M; Emans N; Korff T; Stoldt V; Gressner AM; Kiefer P
Growth Factors; 2005 Jun; 23(2):87-95. PubMed ID: 16019430
[TBL] [Abstract][Full Text] [Related]
14. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures.
Siehler S; Nunn C; Zupanc GK; Hoyer D
Auton Autacoid Pharmacol; 2005 Jan; 25(1):1-16. PubMed ID: 15659149
[TBL] [Abstract][Full Text] [Related]
15. Atrophic macular degeneration mutations in ELOVL4 result in the intracellular misrouting of the protein.
Ambasudhan R; Wang X; Jablonski MM; Thompson DA; Lagali PS; Wong PW; Sieving PA; Ayyagari R
Genomics; 2004 Apr; 83(4):615-25. PubMed ID: 15028284
[TBL] [Abstract][Full Text] [Related]
16. Helix 8 of the leukotriene B4 receptor is required for the conformational change to the low affinity state after G-protein activation.
Okuno T; Ago H; Terawaki K; Miyano M; Shimizu T; Yokomizo T
J Biol Chem; 2003 Oct; 278(42):41500-9. PubMed ID: 12902330
[TBL] [Abstract][Full Text] [Related]
17. Leptin receptor activation depends on critical cysteine residues in its fibronectin type III subdomains.
Zabeau L; Defeau D; Iserentant H; Vandekerckhove J; Peelman F; Tavernier J
J Biol Chem; 2005 Jun; 280(24):22632-40. PubMed ID: 15840566
[TBL] [Abstract][Full Text] [Related]
18. Novel antibody hinge regions for efficient production of CH2 domain-deleted antibodies.
Glaser SM; Hughes IE; Hopp JR; Hathaway K; Perret D; Reff ME
J Biol Chem; 2005 Dec; 280(50):41494-503. PubMed ID: 16221669
[TBL] [Abstract][Full Text] [Related]
19. In-Membrane Chemical Modification (IMCM) for Site-Specific Chromophore Labeling of GPCRs.
Sušac L; O'Connor C; Stevens RC; Wüthrich K
Angew Chem Int Ed Engl; 2015 Dec; 54(50):15246-9. PubMed ID: 26545333
[TBL] [Abstract][Full Text] [Related]
20. Engineering peptide therapeutics using MIMETIBODY™ technology.
Picha K; Huang C; Bugelski P; O'Neil K
Methods Mol Biol; 2014; 1088():125-45. PubMed ID: 24146401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
